Zacks Research Raises Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of Kodiak Sciences in a research report issued to clients and investors on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will earn ($1.10) per share for the quarter, up from their previous forecast of ($1.13). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.52) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($1.04) EPS and FY2026 earnings at ($3.82) EPS.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01.

Separately, HC Wainwright restated a “neutral” rating and set a $3.00 price objective on shares of Kodiak Sciences in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $3.74 on Friday. The stock has a 50 day simple moving average of $2.76 and a 200-day simple moving average of $2.95. Kodiak Sciences has a 1-year low of $1.37 and a 1-year high of $7.77. The company has a market cap of $196.48 million, a price-to-earnings ratio of -0.84 and a beta of 2.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Diversified Trust Co purchased a new stake in Kodiak Sciences during the 1st quarter valued at about $83,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $68,000. RIA Advisory Group LLC acquired a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $489,000. Susquehanna Fundamental Investments LLC purchased a new position in Kodiak Sciences during the first quarter worth approximately $236,000. Finally, Sei Investments Co. acquired a new position in Kodiak Sciences during the first quarter worth $595,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.